1Operating loss improved by 52.7% to -$20.1 million, reflecting significant expense reduction as the company transitioned from its major NAVIGATE clinical trial activities.
2Net loss narrowed by 34.5% to -$30.8 million, while diluted EPS improved to -$0.48 from -$0.76, demonstrating progress in cost management despite the development-stage business model.
3Cash used in operating activities was -$23.9 million, representing a substantial reduction from the prior year's -$41.8 million, aligning with decreased research and development spending.
4The company's expense structure benefited from decreased non-cash stock-based compensation and lower payroll costs due to fewer research and development employees, partially offset by other administrative cost increases.
5Galectin remains in the development stage with no revenues to date and anticipates continued losses for the foreseeable future, with liquidity dependent on external funding sources.
6Management notes that cash operating expenses decreased principally due to reduced research and development activities related to the NAVIGATE clinical trial and associated activities.